Jefferies Group LLC reissued their buy rating on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in a research note released on Monday, July 31st. The brokerage currently has a $36.00 price objective on the biotechnology company’s stock.
A number of other brokerages also recently commented on ACRS. Guggenheim reiterated a buy rating and issued a $40.00 price objective on shares of Aclaris Therapeutics in a research report on Thursday, April 6th. BidaskClub upgraded Aclaris Therapeutics from a hold rating to a buy rating in a research report on Monday, July 24th. ValuEngine downgraded Aclaris Therapeutics from a hold rating to a sell rating in a research report on Tuesday, June 6th. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Friday, June 16th. They set an overweight rating and a $50.00 target price for the company. Finally, Zacks Investment Research downgraded Aclaris Therapeutics from a hold rating to a sell rating in a research report on Friday, May 12th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $39.00.
Aclaris Therapeutics (NASDAQ:ACRS) traded up 8.95% during midday trading on Monday, hitting $25.08. The company had a trading volume of 1,243,235 shares. Aclaris Therapeutics has a one year low of $19.30 and a one year high of $33.25. The company’s 50 day moving average is $27.77 and its 200-day moving average is $27.95. The company’s market cap is $670.54 million.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12. On average, equities analysts predict that Aclaris Therapeutics will post ($3.10) EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in Aclaris Therapeutics by 29.2% in the fourth quarter. State Street Corp now owns 170,630 shares of the biotechnology company’s stock valued at $4,631,000 after buying an additional 38,570 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $4,739,000. Norges Bank acquired a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $900,000. Teachers Advisors LLC increased its position in shares of Aclaris Therapeutics by 24.9% in the fourth quarter. Teachers Advisors LLC now owns 17,249 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 3,435 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $355,000. Institutional investors and hedge funds own 88.64% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.